Rezultati - Jianchang Lin

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects

    Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects od Eric R. Fedyk, Lin‐Pierre Zhao, Annelize Koch, Glennda Smithson, Jose Estevam, Grace Chen, Gëzim Lahu, Stefan Roepcke, Jianchang Lin, Lachy McLean

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations

    Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations od Sai‐Hong Ignatius Ou, Huamao Mark Lin, Jin‐Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Danny Nguyen, Joel W. Neal

    Izdano 2023
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

    Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies od David C. Smith, Thea Kalebic, Jeffrey R. Infante, Lillian L. Siu, Daniel M. Sullivan, Gordana Vlahovic, John Kauh, Feng Gao, Allison Berger, Stephen Tirrell, Neeraj Gupta, Alessandra Di Bacco, Deborah Berg, Guohui Liu, Jianchang Lin, Ai-Min Hui, John A. Thompson

    Izdano 2015
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory m... od María‐Victoria Mateos, Tamás Masszi, Norbert Grząśko, Markus Hansson, Irwindeep Sandhu, Luděk Pour, Luísa Viterbo, Sharon Jackson, Anne‐Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Helgi van de Velde, Paul G. Richardson, Philippe Moreau

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

    Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma od Shaji Kumar, Philippe Moreau, Parameswaran Hari, María‐Victoria Mateos, Heinz Ludwig, Chaim Shustik, Tamás Masszi, Andrew Spencer, Roman Hájek, Kenneth Romeril, Irit Avivi, Anna Marina Liberati, Monique C. Minnema, Hermann Einsele, Sagar Lonial, Deborah Berg, Jianchang Lin, Neeraj Gupta, Dixie‐Lee Esseltine, Paul G. Richardson

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer od Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang‐We Kim, James Chih‐Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, M.R. García Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao Mark Lin, Minal Mehta, Pasi A. Jänne

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

    Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial od Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylvie Vincent, Steven Zhang, Jianchang Lin, Veronica Bunn, Shu Jin, Shuanglian Li, Pasi A. Jänne

    Izdano 2021
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients od Hervé Avet‐Loiseau, Nizar J. Bahlis, Wee Joo Chng, Tamás Masszi, Luísa Viterbo, Luděk Pour, Peter Ganly, Antonio Palumbo, Michèle Cavo, Christian Langer, Andrzej Pluta, Arnon Nagler, Shaji Kumar, Dina Ben‐Yehuda, S. Vincent Rajkumar, Jesús F. San Miguel, Deborah Berg, Jianchang Lin, Helgi van de Velde, Dixie‐Lee Esseltine, Alessandra Di Bacco, Philippe Moreau, Paul G. Richardson

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma od Philippe Moreau, Tamás Masszi, Norbert Grząśko, Nizar J. Bahlis, Markus Hansson, Luděk Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W. Baker, Sharon Jackson, Anne-Marie Stoppa, David R. Simpson, Peter Gimsing, Antonio Palumbo, Laurent Garderet, Michèle Cavo, Shaji Kumar, Cyrille Touzeau, Francis K. Buadi, Jacob P. Laubach, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Ai-Min Hui, Helgi van de Velde, Paul G. Richardson

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: